Hiroki Izumi

1.8k total citations
68 papers, 528 citations indexed

About

Hiroki Izumi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hiroki Izumi has authored 68 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Hiroki Izumi's work include Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (22 papers) and Cancer therapeutics and mechanisms (12 papers). Hiroki Izumi is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (22 papers) and Cancer therapeutics and mechanisms (12 papers). Hiroki Izumi collaborates with scholars based in Japan, United States and Spain. Hiroki Izumi's co-authors include Eiji Shimizu, Toshinori Ando, J. Silvio Gutkind, Yusuke Goto, Akira Yamasaki, Zhiyong Wang, Mara Gilardi, Nadia Arang, Masahiro Kodani and Xiaodong Feng and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Hiroki Izumi

61 papers receiving 519 citations

Peers

Countries citing papers authored by Hiroki Izumi

Since Specialization

Citations

This map shows the geographic impact of Hiroki Izumi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroki Izumi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroki Izumi more than expected).

Fields of papers citing papers by Hiroki Izumi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroki Izumi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroki Izumi. The network helps show where Hiroki Izumi may publish in the future.

Co-authorship network of co-authors of Hiroki Izumi

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroki Izumi. A scholar is included among the top collaborators of Hiroki Izumi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroki Izumi. Hiroki Izumi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Impact of Hyperbolic Discounting on Asset Accumulation for Later Life: A Study of Active Investors Aged 65 Years and over in Japan 2025 ·Risks ·(unknown), (unknown), Hiroki Izumi, (unknown), Mostafa Saidur Rahim Khan, Yoshihiko Kadoya	2
2	Economic Rationality and Health Behavior: Investigating the Link Between Financial Literacy and the BMI 2025 ·Behavioral Sciences ·Kenji Ogura, (unknown), (unknown), Shin Aizawa, (unknown), Hiroki Izumi, Mostafa Saidur Rahim Khan, Yoshihiko Kadoya	0
3	Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study 2025 ·Cancer Research Communications ·Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka, Katsunori Shinozaki, (unknown), Hiroki Hara, Yukiya Narita, Takeshi Shiraishi, (unknown), Akihito Tsuji, Kunihiro Tsuji, Naohiro Watanabe, Hiroshi Tanaka, (unknown), Kensei Yamaguchi, Hiroki Izumi, (unknown), Hideaki Suna	0
4	1853MO Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01 2025 ·Annals of Oncology ·Byoung Chul Cho, J.T.J.N. Hiltermann, Hiroki Izumi, Mariana Brandão, (unknown), Pongwut Danchaivijitr, Enriqueta Felip, Gwo Fuang Ho, (unknown), Yongsheng Li, (unknown), (unknown), Els Wauters, (unknown), Tatsuya Yoshida, (unknown), Ikbel Achour, (unknown), (unknown), Yulei Wang	0
5	Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study 2024 ·ESMO Open ·Seiji Niho, Yasuhiro Gotô, (unknown), Haruko Daga, Kana Ohashi, Toshiaki Takahashi, Hiroshi Tanaka, Jun Sakakibara‐Konishi, Yuki Hattori, Masahiro Morise, (unknown), (unknown), Hiroki Izumi, Shunya Matsumoto, Kiyotaka Yoh, Shogo Nomura, (unknown)	2
6	Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP). 2024 ·Journal of Clinical Oncology ·Shigeki Umemura, Chih‐Hsi S. Kuo, Virote Sriuranpong, Muthukkumaran Thiagarajan, Charuwan Akewanlop, (unknown), Yuji Shibata, (unknown), Tatsuya Ikeda, (unknown), (unknown), Christer Svedman, Takashi Seto, Hiroki Izumi, (unknown), Kōichi Goto	0
7	Efficacy of immunotherapy in first-line treatment for non-small cell lung cancer with HER2 mutation: Results from LC-SCRUM-Asia. 2024 ·Journal of Clinical Oncology ·(unknown), Hibiki Udagawa, Shingo Matsumoto, Hiroki Izumi, Yuichiro Ohe, Terufumi Kato, Kazumi Nishino, Shingo Miyamoto, (unknown), Kenichi Chikamori, Masato Shingyoji, Yuki Sato, Satoshi Hara, (unknown), Koichi Azuma, Tetsuya Sakai, Yoshitaka Zenke, Shigeki Umemura, Kiyotaka Yoh, Kōichi Goto	1
8	Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism 2024 ·Cancer Prevention Research ·Xingyu Wu, (unknown), Keiichi Koshizuka, (unknown), (unknown), Kuniaki Sato, Hiroki Izumi, Yusuke Goto, Michael M. Allevato, Kris C. Wood, Scott M. Lippman, J. Silvio Gutkind	2
9	Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort 2024 ·Cancer Research Communications ·Makoto Nishio, Shuji Murakami, Hisato Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, (unknown), (unknown), (unknown), (unknown), Taro Semba, Koichi Azuma	2
10	Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update 2024 ·Journal of Clinical Oncology ·Afshin Dowlati, Horst-Dieter Hummel, Stéphane Champiat, M.E. Olmedo, Michael Boyer, Kai He, Neeltje Steeghs, Hiroki Izumi, Melissa L. Johnson, Tatsuya Yoshida, Hasna Bouchaab, Hossein Borghaei, Enriqueta Felip, Philipp J. Jost, Shirish M. Gadgeel, (unknown), (unknown), Pablo Martínez, Amanda Parkes, Luis Paz‐Ares	22
11	NETosis in pulmonary pleomorphic carcinoma 2024 ·Cancer Science ·(unknown), Tetsuro Taki, (unknown), Naoya Sakamoto, Shingo Sakashita, Motohiro Kojima, Eri Sugiyama, Shigeki Umemura, Tetsuya Sakai, Hiroki Izumi, Yoshitaka Zenke, Shingo Matsumoto, Kiyotaka Yoh, Makoto Ishii, Masahiro Tsuboi, Kōichi Goto, Genichiro Ishii	0
12	1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01 2023 ·Annals of Oncology ·Mariana Brandão, J.T.J.N. Hiltermann, Els Wauters, Benjamin Solomon, (unknown), Enriqueta Felip, Eelke Gort, Hiroki Izumi, Dongwook Kim, (unknown), Kristoffer Staal Rohrberg, (unknown), Tatsuya Yoshida, (unknown), (unknown), Ikbel Achour, (unknown), Francesca Aroldi, Byoung Chul Cho	6
13	508MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study 2023 ·Annals of Oncology ·Luis Paz‐Ares, M-J. Ahn, Enriqueta Felip, Sabin Handzhiev, (unknown), Hiroki Izumi, Kadoaki Ohashi, M. Majem Tarruella, Jennifer Moriatis Wolf, Martin Reck, (unknown), Fiona Blackhall, Anne‐Marie C. Dingemans, Taofeek K. Owonikoko, Suresh S. Ramalingam, Jacob Sands, Tony Jiang, Sujoy Mukherjee, Ewan M. Anderson, Byoung Chul Cho	1
14	236TiP Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD 2023 ·Annals of Oncology ·Shingo Kitagawa, Yoshitaka Zenke, Kiyotaka Yoh, (unknown), Kei Kunimasa, Shingo Miyamoto, Jun Sakakibara‐Konishi, Ryo Toyozawa, (unknown), Seiji Niho, Kaname Nosaki, Hiroki Izumi, Tetsuya Sakai, Shigeki Umemura, Eri Sugiyama, Kazuhiro Murai, Shingo Matsumoto, Masahiro Tsuboi, Kōichi Goto	1
15	1276P Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD 2023 ·Annals of Oncology ·Kiyotaka Yoh, Yoshitaka Zenke, Shingo Kitagawa, (unknown), Tatsuzo Kasugai, Haruko Daga, Kei Kunimasa, Terufumi Kato, Ichiro Nakachi, (unknown), (unknown), Hiroki Izumi, Tetsuya Sakai, Shigeki Umemura, Eri Sugiyama, Kazuhiro Murai, (unknown), Masahiro Tsuboi, Kōichi Goto	1
16	1282P Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD 2023 ·Annals of Oncology ·Yoshitaka Zenke, Kiyotaka Yoh, Shingo Kitagawa, (unknown), Tatsuzo Kasugai, Haruko Daga, Kei Kunimasa, Terufumi Kato, Ichiro Nakachi, Atsushi Osoegawa, Shingo Miyamoto, Hiroki Izumi, Tetsuya Sakai, Shigeki Umemura, Eri Sugiyama, Kazuhiro Murai, Shingo Matsumoto, Masahiro Tsuboi, Kōichi Goto	1
17	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer 2021 ·Cancer Research ·Yukie Kashima, (unknown), Ayako Suzuki, (unknown), Ikei S. Kobayashi, (unknown), Hibiki Udagawa, Hiroki Izumi, Yuji Shibata, Kosuke Tanaka, Masanori Fujii, Akihiro Ohashi, Masahide Seki, Kōichi Goto, Katsuya Tsuchihara, Yutaka Suzuki, Susumu Kobayashi	49
18	Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer 2020 ·Molecular Cancer Therapeutics ·Hiroki Izumi, Zhiyong Wang, Yusuke Goto, Toshinori Ando, Xingyu Wu, Xuefeng Zhang, Hua Li, Daniel E. Johnson, Jennifer R. Grandis, J. Silvio Gutkind	24
19	Generation of Embryonic Stem Cell Lines from Immature Rabbit Ovarian Follicles 2012 ·Stem Cells and Development ·Takeshi Teramura, (unknown), John P. Frampton, (unknown), (unknown), (unknown), Hiroki Izumi, (unknown), Yuta Onodera, Toshiyuki Takehara, Kanji Fukuda, Yoshihiko Hosoi	2
20	Experimental combination chemotherapy of pirarubicin with various antitumor drugs against P388 murine leukemia. 1994 ·PubMed ·Hiroki Izumi, Shin‐ichi Hirano, (unknown), (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact